Combining mutations in HIV‐1 protease to understand mechanisms of resistance
暂无分享,去创建一个
Irene T Weber | Robert W Harrison | Yuan-Fang Wang | J. Louis | I. Weber | R. Harrison | J. Tőzsér | B. Mahalingam | P. Boross | Peter Boross | Jozsef Tozser | Bhuvaneshwari Mahalingam | John M Louis | Christopher C Fischer | Yuan‐Fang Wang | Christopher C. Fischer
[1] J. Louis,et al. Structural implications of drug‐resistant mutants of HIV‐1 protease: High‐resolution crystal structures of the mutant protease/substrate analogue complexes , 2001, Proteins.
[2] P. Harrigan,et al. Human Immunodeficiency Virus Type 1 Protease Cleavage Site Mutations Associated with Protease Inhibitor Cross-Resistance Selected by Indinavir, Ritonavir, and/or Saquinavir , 2001, Journal of Virology.
[3] Z. Otwinowski,et al. [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[4] T. Merigan,et al. Multiple Concurrent Reverse Transcriptase and Protease Mutations and Multidrug Resistance of HIV-1 Isolates from Heavily Treated Patients , 1998, Annals of Internal Medicine.
[5] R. Stroud,et al. Structure of the protease from simian immunodeficiency virus: complex with an irreversible nonpeptide inhibitor. , 1993, Biochemistry.
[6] G. Cohen. Align : A program to superimpose protein coordinates, accounting for insertions and deletions , 1997 .
[7] G. Sheldrick,et al. SHELXL: high-resolution refinement. , 1997, Methods in enzymology.
[8] G. Marius Clore,et al. Autoprocessing of HIV-1 protease is tightly coupled to protein folding , 1999, Nature Structural Biology.
[9] D. Ho,et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease , 1996, Antimicrobial agents and chemotherapy.
[10] J. Zou,et al. Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.
[11] J. Louis,et al. Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease. , 1998, Biochemistry.
[12] P. Massip,et al. Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV‐1 infection , 2000, Journal of medical virology.
[13] V. Trouplin,et al. Retracing the Evolutionary Pathways of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors: Virus Fitness in the Absence and in the Presence of Drug , 2000, Journal of Virology.
[14] Brendan A. Larder,et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples , 2000, AIDS.
[15] B. Korber,et al. HIV sequence compendium 2002 , 2002 .
[16] Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates. , 1997, European journal of biochemistry.
[17] M. Sternberg,et al. An analysis of conformational changes on protein-protein association: implications for predictive docking. , 1999, Protein engineering.
[18] J. Louis,et al. Structural basis for specificity of retroviral proteases. , 1998, Biochemistry.
[19] H. Kräusslich,et al. Cleavage of Human Immunodeficiency Virus Type 1 Proteinase from the N-Terminally Adjacent p6* Protein Is Essential for Efficient Gag Polyprotein Processing and Viral Infectivity , 1998, Journal of Virology.
[20] R. Zahler. Enzyme Structure and Mechanism , 1979, The Yale Journal of Biology and Medicine.
[21] Martine Peeters,et al. Genetic Diversity of Protease and Reverse Transcriptase Sequences in Non-Subtype-B Human Immunodeficiency Virus Type 1 Strains: Evidence of Many Minor Drug Resistance Mutations in Treatment-Naive Patients , 2000, Journal of Clinical Microbiology.
[22] A Wlodawer,et al. Programming the Rous Sarcoma Virus Protease to Cleave New Substrate Sequences (*) , 1996, The Journal of Biological Chemistry.
[23] F. Mammano,et al. Loss of Viral Fitness Associated with Multiple Gag and Gag-Pol Processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors In Vivo , 1998, Journal of Virology.
[24] J. Navaza,et al. AMoRe: an automated package for molecular replacement , 1994 .
[25] L Hong,et al. Crystal structure of an in vivo HIV‐1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistance , 2000, Protein science : a publication of the Protein Society.
[26] A Wlodawer,et al. Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate. , 1998, Biochemistry.
[27] J. Martinez-Picado,et al. Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1 , 1999, Journal of Virology.
[28] B. Larder,et al. Mutations in Retroviral Genes Associated with Drug Resistance , 1996 .
[30] A Wlodawer,et al. Human Immunodeficiency Virus, Type 1 Protease Substrate Specificity Is Limited by Interactions between Substrate Amino Acids Bound in Adjacent Enzyme Subsites (*) , 1996, The Journal of Biological Chemistry.
[31] S. Gulnik,et al. Drug resistance mutations can affect dimer stability of HIV‐1 protease at neutral pH , 1999, Protein science : a publication of the Protein Society.
[32] D. Ho,et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir , 1996, Nature Medicine.
[33] J. Louis,et al. Influence of flanking sequences on the dimer stability of human immunodeficiency virus type 1 protease. , 1996, Biochemistry.
[34] T. Schneider,et al. Objective comparison of protein structures: error-scaled difference distance matrices. , 2000, Acta crystallographica. Section D, Biological crystallography.
[35] J. Louis,et al. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. , 2000, European journal of biochemistry.
[36] Irene T. Weber,et al. Studies on the Symmetry and Sequence Context Dependence of the HIV-1 Proteinase Specificity* , 1997, The Journal of Biological Chemistry.
[37] Axel T. Brunger,et al. X-PLOR Version 3.1: A System for X-ray Crystallography and NMR , 1992 .
[38] J S Sack,et al. CHAIN: a crystallographic modeling program. , 1997, Methods in enzymology.
[39] A. Kaplan,et al. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions , 1994, Journal of virology.